Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corporation

In a report released today, Matthew Taylor from Jefferies reiterated a Buy rating on Boston Scientific, with a price target of $132.00. Taylor cove...

Jefferies Reaffirms Their Buy Rating on Boston Scientific (BSX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Azenta (AZTA – Research Report) and Boston Scientifi...

Analysts Are Bullish on Top Healthcare Stocks: Azenta (AZTA), Boston Scientific (BSX)

The sheer number of exchange-traded funds (ETFs) available means investors can struggle to identify the best way in. TipRanks’ AI analyst has zeroe...

3 Best ETFs to Invest In, According to AI Analyst, 12/09/2025

Blackstone Minerals Ltd ( ($AU:BSX) ) has issued an update. Blackstone Minerals Ltd announced that all resolutions proposed at its Annual General M...

Blackstone Minerals Ltd Secures Shareholder Approval at AGM

Boston Scientific ( ($BSX) ) has provided an update. On November 18, 2025, Boston Scientific‘s Board of Directors approved the 2026 Annual Bonus Pl...

Boston Scientific Approves 2026 Bonus Plan

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC – Research Report) and ...

Market Cap	$137.17B	P/E Ratio	30.45
52W High	$109.50	52W Low	$85.98
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	22.2%	52W Position	28.1%
Overall Score	46	Value Score	45
Quality Score	57	Technical Score	36

EPS Current Est	$3.04	EPS Next Est	$3.45
EPS Growth Est	+13.5%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BSX	$92.58	+0.90%	7.77M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BSX	$92.58	+0.9%	7.77M
3
4
5
6

BSX

BSX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Boston Scientific Corporation Data in Excel

Get Boston Scientific Corporation Data in Excel